Age‐specific reference ranges of serum anti‐müllerian hormone in healthy women and its application in diagnosis of polycystic ovary syndrome: a population study

Li, Raymond; He, Yingna; Li, Rong; Wong, Ching Yin Grace; Sy, Barre; Lam, Ching Wan; Lam, Karen Siu Ling; Peng, Hongmei; Mu, Sha; Schooling, Mary; Yeung, William Shu Biu; Ho, Pak Chung; Ng, Ernest Hung Yu

doi:10.1111/1471-0528.16147

Cited by 21 publications

(24 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meanwhile, the diagnostic performance of AMH for PCOS with age‐group‐specific reference limits was not entirely satisfactory. Additionally, the age‐specific reference limits reported in previous studies 9,10 and the age‐group‐specific reference limits suggested by the assay manufacturer also only offered limited performance for our study population (Table 3). This may be due to overlaps in the distribution of AMH concentrations from healthy women and PCOS patients in the Korean sample population.…”

Section: Discussionmentioning

confidence: 91%

“…Therefore, it could be more appropriate to use multiple age‐related cutoff values instead of a universal cutoff as a diagnostic threshold. Previous studies have reported that age‐specific reference limits or multiples of the median (MoM) can significantly increase the diagnostic utility of AMH 9,10 …”

Section: Discussionmentioning

confidence: 99%

“…Various cutoff values for serum AMH have been proposed for discriminating PCOS women from healthy women 8 . However, few studies have evaluated age‐related or age‐specific reference intervals of serum AMH, especially for data generated from automated assays 9–12 . Moreover, PCOS prevalence and characteristics of the control population would influence diagnostic performance in a real‐world setting.…”

Section: Introductionmentioning

confidence: 99%

“… 8 However, few studies have evaluated age‐related or age‐specific reference intervals of serum AMH, especially for data generated from automated assays. 9 , 10 , 11 , 12 Moreover, PCOS prevalence and characteristics of the control population would influence diagnostic performance in a real‐world setting. Additionally, ethnicity, which is strongly associated with anthropometric characteristics, risk for other benign gynecologic conditions, and the age range of the subject population, can all affect determination of appropriate cutoff values and overall accuracy of an AMH test.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Age‐group‐specific reference intervals for anti‐Müllerian hormone and its diagnostic performance for polycystic ovary syndrome in a Korean population

Song

Park

Cho

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background We established age‐group‐specific reference intervals for serum anti‐Müllerian hormone (AMH) levels in a Korean population and investigated the effectiveness of AMH assay for polycystic ovary syndrome (PCOS) diagnosis. Methods We analyzed serum levels of AMH, follicle‐stimulating hormone (FSH), and luteinizing hormone (LH) from 1540 Korean women. Subjects were divided into three groups: healthy, benign gynecologic diseases, and PCOS. Age‐group‐specific reference intervals and AMH diagnostic performance were estimated. Results The PCOS group had a median AMH level of 7.0 µg/L, which was higher than for the healthy (1.8 µg/L) and the benign gynecologic diseases (2.7 µg/L) groups. The upper 97.5% reference limits for age groups 12–20 years, 21–34 years, and 35–46 years were 13.2 µg/L, 15.8 µg/L, and 6.6 µg/L, respectively. The area under the curve (AUC) values to estimate AMH ability to discriminate PCOS from healthy women for each age group were 0.741, 0.785, and 0.789, respectively. AUCs for LH/FSH were 0.719, 0.672, and 0.590. Conclusions The better diagnostic ability of AMH over LH/FSH in women of late childbearing ages indicates that age and other clinical characteristics should be considered when interpreting these test results.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Age‐group‐specific reference intervals for anti‐Müllerian hormone and its diagnostic performance for polycystic ovary syndrome in a Korean population

Song

Park

Cho

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“… 35 In addition, AMH varies for different ages, so the set of year-by-year age-specific reference ranges of serum AMH levels in Chinese women could be a good reference. 36 The participants need to undergo transvaginal ultrasound in our study, so women who were virgins were not included in our study.…”

Section: Commentsmentioning

confidence: 99%

Prevalence of oligomenorrhea among women of childbearing age in China: A large community-based study

Zheng

Shang

et al. 2020

Womens Health (Lond Engl)

View full text Add to dashboard Cite

Objective: To investigate the prevalence and the related characteristics of oligomenorrhea among women within childbearing age in China. Study design: A large-scale community-based investigation was conducted from 2013 to 2015. A total of 12,964 women aged 18–49 years from 9 provinces/municipalities in China were recruited for healthcare screening in local community health centers. Outcome measures include clinical history, ultrasonographic exam, and hormonal and metabolic parameters. Results: Among women within childbearing age in China, the prevalence of oligomenorrhea was 12.2% (1,579/12,964). Both sociodemographic factors and medical history were significantly associated with oligomenorrhea ( P < 0.05). In such women, the prevalence of obesity, acne, seborrhea, acanthosis, larger ovarian size, and polycystic ovarian morphology was higher when compared with normal women; the prevalence of anti-Mullerian hormone, total testosterone, and androstenedione ( P < 0.05) was higher as well. The infertility rates of all women were higher in the oligomenorrhea group (17.2%, 272⁄1,579) than in the non-oligomenorrhea group (9.0%, 1,024⁄11,385), and among women without contraception, for the oligomenorrhea group, the infertility rate was 32.5% (128⁄394), and for the non-oligomenorrhea group, 17.9% (400⁄2,240). In the oligomenorrhea group, 57.4% (156/272) of the women underwent treatments for infertility, which was higher than the non-oligomenorrhea group 36.1% (370/1,024). Conclusions: Obesity, acne, seborrhea, acanthosis, larger ovarian size, and polycystic ovarian morphology were significantly associated with oligomenorrhea. The increase of anti-Mullerian hormone, total testosterone, and androstenedione level was also demonstrated in the oligomenorrhea group. Higher prevalence of infertility and medical treatment rate was observed in women with oligomenorrhea.

show abstract

Comparison of the multiples of the median of serum anti‐müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case–control study

Lai,

Lau,

Ngu

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

IntroductionChemotherapy is crucial in treating gestational trophoblastic neoplasia (GTN), but its impact on gonadotoxicity is unclear.Materials and MethodsThis case–control study included 57 GTN patients and 19 age‐matched patients with molar pregnancies (MP) in 2012–2018. Multiples of the median (MoM) of the serum AMH levels were compared between the two groups, and between patients using single‐agent and combination chemotherapy, at baseline, 6, 12, and 24 months after treatment. Their pregnancy outcomes were also compared.ResultsThere was no significant difference in the MoM of serum AMH between GTN and MP groups at all time points. Single‐agent chemotherapy did not adversely affect the MoM. However, those receiving combination chemotherapy had lower MoM than those receiving single‐agent chemotherapy at all time points. The trend of decline from the baseline was marginally significant in patients with combination chemotherapy, but the drop was only significant at 12 months (Z = −2.69, p = 0.007) but not at 24 months (Z = −1.90; p = 0.058). Multivariable analysis revealed that combination chemotherapy did not affect the MoM. There was no significant difference in the 4‐year pregnancy rate and the livebirth rate between the single‐agent and combination groups who attempting pregnancy, but it took 1 year longer to achieve the first pregnancy in the combination group compared to the single‐agent group (2.88 vs. 1.88 years).ConclusionThis study showed combination chemotherapy led to a decreasing trend of MoM of serum AMH especially at 12 months after treatment, but the drop became static at 24 months. Although pregnancy is achievable, thorough counseling is still needed in this group especially those wish to achieve pregnancy 1–2 years after treatment or with other risk factors.

show abstract

Age‐specific reference ranges of serum anti‐müllerian hormone in healthy women and its application in diagnosis of polycystic ovary syndrome: a population study

Cited by 21 publications

References 37 publications

Age‐group‐specific reference intervals for anti‐Müllerian hormone and its diagnostic performance for polycystic ovary syndrome in a Korean population

Age‐group‐specific reference intervals for anti‐Müllerian hormone and its diagnostic performance for polycystic ovary syndrome in a Korean population

Prevalence of oligomenorrhea among women of childbearing age in China: A large community-based study

Comparison of the multiples of the median of serum anti‐müllerian hormone and pregnancy outcomes in patients with gestational trophoblastic disease: A case–control study

Contact Info

Product

Resources

About